{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T19:45:29Z","timestamp":1790451929375,"version":"4.1.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2021,11,8]],"date-time":"2021-11-08T00:00:00Z","timestamp":1636329600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,11,8]],"date-time":"2021-11-08T00:00:00Z","timestamp":1636329600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urogynecol J"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1007\/s00192-021-05013-4","type":"journal-article","created":{"date-parts":[[2021,11,8]],"date-time":"2021-11-08T13:02:37Z","timestamp":1636376557000},"page":"1103-1123","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Efficacy and safety of quinolones vs. other antimicrobials for the treatment of uncomplicated urinary tract infections in adults: a systematic review and meta-analysis"],"prefix":"10.1007","volume":"33","author":[{"given":"Kaicheng","family":"Yan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Man","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuting","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,11,8]]},"reference":[{"issue":"4","key":"5013_CR1","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/S0924-8579(01)00303-X","volume":"17","author":"AR Ronald","year":"2001","unstructured":"Ronald AR, et al. Urinary tract infection in adults: research priorities and strategies. Int J Antimicrob Agents. 2001;17(4):343\u20138.","journal-title":"Int J Antimicrob Agents"},{"issue":"2","key":"5013_CR2","first-page":"65","volume":"88","author":"PA Margariti","year":"1997","unstructured":"Margariti PA, Astorri AL, Mastromarino C. Urinary tract infections: risk factors and therapeutic trends. Recenti Prog Med. 1997;88(2):65\u20138.","journal-title":"Recenti Prog Med"},{"issue":"1","key":"5013_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.idc.2013.09.003","volume":"28","author":"B Foxman","year":"2014","unstructured":"Foxman B. Urinary tract infection syndromes: occurrence, recurrence, bacteriology, risk factors, and disease burden. Infect Dis Clin N Am. 2014;28(1):1\u201313.","journal-title":"Infect Dis Clin N Am"},{"issue":"8","key":"5013_CR4","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1056\/NEJM198208193070802","volume":"307","author":"WE Stamm","year":"1982","unstructured":"Stamm WE, et al. Diagnosis of coliform infection in acutely dysuric women. N Engl J Med. 1982;307(8):463\u20138.","journal-title":"N Engl J Med"},{"issue":"4","key":"5013_CR5","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1086\/520427","volume":"29","author":"JW Warren","year":"1999","unstructured":"Warren JW, et al. Guidelines for antimicrobial treatment of uncomplicated acute bacterial cystitis and acute pyelonephritis in women. Infectious Diseases Society of America (IDSA). Clin Infect Dis. 1999;29(4):745\u201358.","journal-title":"Clin Infect Dis"},{"issue":"5","key":"5013_CR6","doi-asserted-by":"publisher","first-page":"e103","DOI":"10.1093\/cid\/ciq257","volume":"52","author":"K Gupta","year":"2011","unstructured":"Gupta K, et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis. 2011;52(5):e103\u201320.","journal-title":"Clin Infect Dis"},{"key":"5013_CR7","unstructured":"Tamma PD, Aitken SLA, Bonomo RA, et al. Infectious Diseases Society of America Antimicrobial Resistant Treatment Guidance: Gram-Negative Bacterial Infections 2020. http:\/\/guide.medlive.cn\/."},{"key":"5013_CR8","unstructured":"Bonkat G, Bartoletti R, Bruy\u00e8re F, et al. EAU Guidelines on Urological Infections. 2020. http:\/\/guide.medlive.cn\/."},{"key":"5013_CR9","doi-asserted-by":"publisher","first-page":"103291","DOI":"10.1016\/j.bioorg.2019.103291","volume":"92","author":"P Dhiman","year":"2019","unstructured":"Dhiman P, et al. Recent advances in the synthetic and medicinal perspective of quinolones: A review. Bioorg Chem. 2019;92:103291.","journal-title":"Bioorg Chem"},{"issue":"4","key":"5013_CR10","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/S0094-0143(05)70214-7","volume":"26","author":"RU Anderson","year":"1999","unstructured":"Anderson RU. Management of lower urinary tract infections and cystitis. Urol Clin North Am. 1999;26(4):729\u201335. viii.","journal-title":"Urol Clin North Am"},{"key":"5013_CR11","volume":"3","author":"V Rafalsky","year":"2006","unstructured":"Rafalsky V, Andreeva I, Rjabkova E. Quinolones for uncomplicated acute cystitis in women. Cochrane Database Syst Rev. 2006;3:CD003597.","journal-title":"Cochrane Database Syst Rev"},{"key":"5013_CR12","unstructured":"Administration, USFDA, FDA Drug Safety Communication: FDA advises restricting fluoroquinolone antibiotic use for certain uncomplicated infections; warns about disabling side effects that can occur together. Updated 2018-12-20, 2016. https:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm500143.htm."},{"issue":"4","key":"5013_CR13","first-page":"19","volume":"36","author":"M Meadows","year":"2002","unstructured":"Meadows M. The FDA's drug review process: ensuring drugs are safe and effective. FDA Consum. 2002;36(4):19\u201324.","journal-title":"FDA Consum"},{"issue":"3","key":"5013_CR14","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/s15010-012-0257-2","volume":"40","author":"A Dalhoff","year":"2012","unstructured":"Dalhoff A. Resistance surveillance studies: a multifaceted problem--the fluoroquinolone example. Infection. 2012;40(3):239\u201362.","journal-title":"Infection"},{"issue":"Suppl 2","key":"5013_CR15","doi-asserted-by":"publisher","first-page":"S113","DOI":"10.1086\/428051","volume":"41","author":"VT Andriole","year":"2005","unstructured":"Andriole VT. The quinolones: past, present, and future. Clin Infect Dis. 2005;41(Suppl 2):S113\u20139.","journal-title":"Clin Infect Dis"},{"issue":"4","key":"5013_CR16","doi-asserted-by":"publisher","first-page":"E878","DOI":"10.9778\/cmajo.20170100","volume":"5","author":"C Tan","year":"2017","unstructured":"Tan C, et al. A decade of outpatient antimicrobial use in older adults in Ontario: a descriptive study. CMAJ Open. 2017;5(4):E878\u201385.","journal-title":"CMAJ Open"},{"issue":"2","key":"5013_CR17","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1080\/00325481.2017.1246055","volume":"129","author":"MS Bader","year":"2017","unstructured":"Bader MS, Loeb M, Brooks AA. An update on the management of urinary tract infections in the era of antimicrobial resistance. Postgrad Med. 2017;129(2):242\u201358.","journal-title":"Postgrad Med"},{"issue":"8","key":"5013_CR18","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1001\/jama.293.8.949","volume":"293","author":"TM Hooton","year":"2005","unstructured":"Hooton TM, et al. Amoxicillin-clavulanate vs ciprofloxacin for the treatment of uncomplicated cystitis in women: a randomized trial. Jama. 2005;293(8):949\u201355.","journal-title":"Jama"},{"issue":"4","key":"5013_CR19","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1002\/cpt1969104534","volume":"10","author":"JD Conklin","year":"1969","unstructured":"Conklin JD, Hailey FJ. Urinary drug excretion in man during oral dosage of different nitrofurantoin formulations. Clin Pharmacol Ther. 1969;10(4):534\u20139.","journal-title":"Clin Pharmacol Ther"},{"key":"5013_CR20","doi-asserted-by":"crossref","unstructured":"Spencer RC, Moseley DJ, Greensmith MJ. Nitrofurantoin modified release versus trimethoprim or co-trimoxazole in the treatment of uncomplicated urinary tract infection in general practice. J Antimicrob Chemother, 1994;33(Suppl A):121-9.","DOI":"10.1093\/jac\/33.suppl_A.121"},{"issue":"4","key":"5013_CR21","doi-asserted-by":"publisher","first-page":"637","DOI":"10.2165\/00003495-199753040-00007","volume":"53","author":"SS Patel","year":"1997","unstructured":"Patel SS, Balfour JA, Bryson HM. Fosfomycin tromethamine. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy as a single-dose oral treatment for acute uncomplicated lower urinary tract infections. Drugs. 1997;53(4):637\u201356.","journal-title":"Drugs"},{"key":"5013_CR22","unstructured":"Grabe M, BM, Bjerklund-Johansen TE, et al. Guidelines on urological infections. In EAU Guidelines edition presented at the 25th EAU Annual Congress, Barcelona 2010. ISBN 978-90-79754-70-0."},{"issue":"4","key":"5013_CR23","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1093\/jac\/dkh414","volume":"54","author":"JL Arredondo-Garc\u00eda","year":"2004","unstructured":"Arredondo-Garc\u00eda JL, et al. Comparison of short-term treatment regimen of ciprofloxacin versus long-term treatment regimens of trimethoprim\/sulfamethoxazole or norfloxacin for uncomplicated lower urinary tract infections: a randomized, multicentre, open-label, prospective study. J Antimicrob Chemother. 2004;54(4):840\u20133.","journal-title":"J Antimicrob Chemother"},{"issue":"5","key":"5013_CR24","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2016-015233","volume":"7","author":"H Ahmed","year":"2017","unstructured":"Ahmed H, et al. Long-term antibiotics for prevention of recurrent urinary tract infection in older adults: systematic review and meta-analysis of randomised trials. BMJ Open. 2017;7(5):e015233.","journal-title":"BMJ Open"},{"issue":"Suppl 4","key":"5013_CR25","doi-asserted-by":"publisher","first-page":"S341","DOI":"10.1086\/382690","volume":"38","author":"DL Paterson","year":"2004","unstructured":"Paterson DL. \"Collateral damage\" from cephalosporin or quinolone antibiotic therapy. Clin Infect Dis. 2004;38(Suppl 4):S341\u20135.","journal-title":"Clin Infect Dis"},{"issue":"5","key":"5013_CR26","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1016\/j.ajog.2016.07.040","volume":"215","author":"JR Price","year":"2016","unstructured":"Price JR, et al. Nitrofurantoin vs other prophylactic agents in reducing recurrent urinary tract infections in adult women: a systematic review and meta-analysis. Am J Obstet Gynecol. 2016;215(5):548\u201360.","journal-title":"Am J Obstet Gynecol"},{"key":"5013_CR27","doi-asserted-by":"crossref","unstructured":"Sanchez GV, et al. In vitro antimicrobial resistance of urinary Escherichia coli isolates among US outpatients from 2000 to 2010. Antimicrob Agents Chemother 2012;56(4):2181-3.","DOI":"10.1128\/AAC.06060-11"},{"issue":"2","key":"5013_CR28","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/s10096-009-0833-2","volume":"29","author":"M Popovic","year":"2010","unstructured":"Popovic M, et al. Fosfomycin: an old, new friend? Eur J Clin Microbiol Infect Dis. 2010;29(2):127\u201342.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"5","key":"5013_CR29","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1016\/j.eururo.2008.05.010","volume":"54","author":"KG Naber","year":"2008","unstructured":"Naber KG, et al. Surveillance study in Europe and Brazil on clinical aspects and Antimicrobial Resistance Epidemiology in Females with Cystitis (ARESC): implications for empiric therapy. Eur Urol. 2008;54(5):1164\u201375.","journal-title":"Eur Urol"},{"key":"5013_CR30","unstructured":"Agency, E.M. Disabling and potentially permanent side effects lead to suspension or restrictions of quinolone and fluoroquinolone antibiotics. Updated 2018-11-16, 2018. https:\/\/www.ema.europa.eu\/en\/news\/disabling-potentially-permanent-side-effects-lead-suspension-restrictions-quinolone-fluoroquinolone."},{"issue":"3","key":"5013_CR31","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1111\/j.1742-1241.2009.02239.x","volume":"64","author":"TE Albertson","year":"2010","unstructured":"Albertson TE, et al. Fluoroquinolones in the management of community-acquired pneumonia. Int J Clin Pract. 2010;64(3):378\u201388.","journal-title":"Int J Clin Pract"},{"key":"5013_CR32","doi-asserted-by":"crossref","unstructured":"Gentry LO. Review of quinolones in the treatment of infections of the skin and skin structure. J Antimicrob Chemother 1991;28(Suppl C):97-110.","DOI":"10.1093\/jac\/28.suppl_C.97"},{"issue":"Suppl 1","key":"5013_CR33","doi-asserted-by":"publisher","first-page":"S179","DOI":"10.1093\/clinids\/10.Supplement_1.S179","volume":"10","author":"N Desplaces","year":"1988","unstructured":"Desplaces N, Acar JF. New quinolones in the treatment of joint and bone infections. Rev Infect Dis. 1988;10(Suppl 1):S179\u201383.","journal-title":"Rev Infect Dis"},{"issue":"5","key":"5013_CR34","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1586\/eri.10.35","volume":"8","author":"AM Noreddin","year":"2010","unstructured":"Noreddin AM, Elkhatib WF. Levofloxacin in the treatment of community-acquired pneumonia. Expert Rev Anti-Infect Ther. 2010;8(5):505\u201314.","journal-title":"Expert Rev Anti-Infect Ther"},{"key":"5013_CR35","unstructured":"Thai T, Salisbury BH, Zito PM. Ciprofloxacin. In: StatPearls. StatPearls Publishing Copyright. 2021;7(4):3015-24."},{"issue":"5","key":"5013_CR36","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/j.cmi.2019.10.016","volume":"26","author":"N Daneman","year":"2020","unstructured":"Daneman N, et al. Fluoroquinolone use for uncomplicated urinary tract infections in women: a retrospective cohort study. Clin Microbiol Infect. 2020;26(5):613\u20138.","journal-title":"Clin Microbiol Infect"}],"container-title":["International Urogynecology Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00192-021-05013-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00192-021-05013-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00192-021-05013-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,19]],"date-time":"2022-05-19T14:05:24Z","timestamp":1652969124000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00192-021-05013-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,8]]},"references-count":36,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["5013"],"URL":"https:\/\/doi.org\/10.1007\/s00192-021-05013-4","relation":{},"ISSN":["0937-3462","1433-3023"],"issn-type":[{"value":"0937-3462","type":"print"},{"value":"1433-3023","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,8]]},"assertion":[{"value":"3 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 October 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 November 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest for all authors"}}]}}